AdAlta Ltd. (AU:1AD) has released an update.
AdAlta Limited, a Melbourne-based clinical stage drug development company, has announced two upcoming investor webinars to discuss its innovative i-body technology and its lead drug candidate, AD-214, which is approaching Phase 2 clinical trials. The company’s CEO, Dr. Tim Oldham, will outline AdAlta’s strategic partnerships, its new immunotherapy strategy AdCella, and development milestones for the next year. These webinars are open for registration and will provide investors an opportunity to engage directly with the company’s leadership.
For further insights into AU:1AD stock, check out TipRanks’ Stock Analysis page.
